Identified 50 years ago, mesenchymal stromal/stem cells (MSCs) immediately generated a
substantial interest among the scientific community because of their differentiation plasticity …

Summary 2018 was the year of the first marketing authorization of an allogeneic stem cell
therapy by the European Medicines Agency. The authorization concerns the use of …

Research into mesenchymal stromal/stem cells (MSCs) has been particularly exciting in the
past five years. Our understanding of mechanisms of MSC-mediated tissue regeneration has …

In recent decades, mesenchymal stromal cells (MSCs) biomedical utilizing has attracted
worldwide growing attention. After the first report of the human MSCs obtaining from the …

As a result of over five decades of investigation, mesenchymal stromal/stem cells (MSCs)
have emerged as a versatile and frequently utilized cell source in the fields of regenerative …

Mesenchymal stem—or stromal—cells (MSCs) have been administered in hundreds of
clinical trials for multiple indications, making them some of the most commonly used …

Mesenchymal stromal cells (MSCs) have been the subject of clinical trials for more than a
generation, and the outcomes of advanced clinical trials have fallen short of expectations …

Following their discovery over 50 years ago, mesenchymal stromal cells (MSCs) have
become one of the most studied cellular therapeutic products by both academia and industry …

In recent decades, research on the therapeutic potential of progenitor cells has advanced
considerably. Among progenitor cells, mesenchymal stromal cells (MSCs) have attracted …

It was shown as long as half a century ago that bone marrow is a source of not only
hematopoietic stem cells, but also stem cells of mesenchymal tissues. Then the term …